Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Ovarian Epithelial 4Neoplasms, Plasma Cell 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Gliosarcoma 3Glioblastoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Brain Neoplasms 2Astrocytoma 2Urinary Bladder Neoplasms 1

Interventions

Cytarabine 6Idarubicin 4Vorinostat 3Tretinoin 3Etoposide 3Daunorubicin 3Azacitidine 3romidepsin 2Thioguanine 2Sorafenib 2Radiotherapy 2Mitoxantrone 2Methotrexate 2Mercaptopurine 2Lenalidomide 2Cyclophosphamide 2sargramostim 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1merphos 1ispinesib 1flt3 ligand protein 1entinostat 1belinostat 1Peripheral Blood Stem Cell Transplantation 1Homoharringtonine 1Filgrastim 1Drug Therapy 1Decitabine 1CK0238273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Promyelocytic, Acute × Drug Therapy × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡